Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,121.37 -7.98 (-0.71%)

Streaming Delayed Price Updated: 3:09 PM EDT, Jun 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗

May 28, 2026

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Via The Motley Fool

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗

May 28, 2026

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Via MarketBeat

Topics Earnings

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗

May 28, 2026

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Via The Motley Fool

Topics ETFs

Is Eli Lilly Stock Outperforming the Nasdaq?

May 28, 2026

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Via Barchart.com

Topics Stocks

Is Johnson & Johnson Stock Outperforming the Dow?

May 28, 2026

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Via Barchart.com

Topics Stocks

5 Undervalued Stocks You Can Buy and Hold Forever ↗

May 28, 2026

Buying and holding stocks is an excellent strategy to increase your wealth.

Via The Motley Fool

3 Healthcare Stocks We Keep Off Our Radar

May 28, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...

Via StockStory

2 Mega-Cap Stocks on Our Buy List and 1 We Find Risky

May 28, 2026

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less roo...

Via StockStory

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗

May 27, 2026

There is no reason to panic just yet.

Via The Motley Fool

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗

May 27, 2026

Eli Lilly's fundamentals matter more than Trump's stock purchases.

Via The Motley Fool

Topics Government

The $4 Billion Reason Eli Lilly Stock Is Up Today

May 27, 2026

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

Via Barchart.com

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗

May 27, 2026

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗

May 27, 2026

A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.

Via The Motley Fool

Topics ETFs

Micron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next. ↗

May 26, 2026

Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.

Via The Motley Fool

Topics Artificial Intelligence Earnings

Is Eli Lilly Stock an Undervalued Stock to Buy? ↗

May 26, 2026

Consumer demand for Eli Lilly's weight-loss treatments continues to rise.

Via The Motley Fool

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗

May 26, 2026

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Via The Motley Fool

Topics Regulatory Compliance

From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave ↗

May 26, 2026

Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.

Via Benzinga

Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants. ↗

May 26, 2026

For some types of restaurants, the damage is bigger.

Via Investor's Business Daily

Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now? ↗

May 26, 2026

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.

Via Investor's Business Daily

Walmart Got Kicked Out of the $1 Trillion Club. Is the Dividend King Stock a No-Brainer Buy Before the End of May? ↗

May 26, 2026

Walmart's recent run of outperformance could be coming to an end.

Via The Motley Fool

Topics Artificial Intelligence Earnings

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗

May 26, 2026

These players are seeing exciting results in clinical trials.

Via The Motley Fool

Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% ↗

May 26, 2026

Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.

Via Benzinga

Don't Buy Viking Therapeutics Stock Until You Read This ↗

May 25, 2026

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Via The Motley Fool

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗

May 25, 2026

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1

May 24, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗

May 24, 2026

Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

Is Viking Therapeutics a Top Takeover Target? ↗

May 23, 2026

Viking's strong obesity drug data continues fueling acquisition speculation.

Via The Motley Fool

MarketBeat Week in Review – 05/18 - 05/22 ↗

May 23, 2026

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Via MarketBeat

Topics Artificial Intelligence Economy

Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗

May 22, 2026

The healthcare sector outperformed the rest of the market over the past week.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.